Disposition of Δ9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein

被引:32
作者
Bonhomme-Faivre, Laurence [1 ,3 ]
Benyamina, Amine [2 ]
Reynaud, Michel [2 ]
Farinotti, Robert [3 ]
Abbara, Chadi [1 ]
机构
[1] Hop Paul Brousse, APHP, Dept Pharmacol & Pharm, F-94800 Villejuif, France
[2] Hop Paul Brousse, APHP, Dept Psychiat & Addictol, F-94800 Villejuif, France
[3] Univ Paris 06, Dept Clin Pharm, UPRES 2706, F-75252 Paris 05, France
关键词
CF1; mice; Delta; 9; tetrahydrocannabinol; digoxin; multidrug resistance; P-glycoprotein; THC;
D O I
10.1111/j.1369-1600.2008.00096.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
P-glycoprotein (P-gp) plays a major role in drug efflux. All the transported substrates are more or less hydrophobic and amphiphatic in nature. Being lipophilic, Delta(9) tetrahydrocannabinol (THC), the main cannabis component, could be a potential P-gp substrate. The aim of this project was to determine the contribution of the mdr1a gene product to THC disposition. Therefore, oral THC and digoxin (substrate test for P-gp) pharmacokinetics have been investigated in the intestinal epithelium and in the brain capillary endothelium of CF1 mdr1a (-/-) mice (mice naturally deficient in P-gp). These pharmacokinetics were compared to THC and digoxin oral pharmacokinetics in wild type mice mdr1a (+/+) (not P-gp deficient). The application of Bailer's method showed that THC total exposure measured by the area under the plasma concentration time curve was 2.17-fold higher in CF1 mice naturally deficient in P-gp than in wild type mice after oral administration of 25 mg/kg of THC, and 2.4-fold higher after oral administration of 33 mu g/kg of digoxin. As a consequence, the oral bioavailability of THC and digoxin was higher in naturally P-gp-deficient mice. We concluded that P-gp limits THC oral uptake and mediates direct drug excretion from the systemic circulation into the intestinal lumen.
引用
收藏
页码:295 / 300
页数:6
相关论文
共 25 条
  • [1] Development and validation of a method for the quantitation of Δ9 tetrahydrocannabinol in human plasma by high performance liquid chromatography after solid-phase extraction
    Abbara, Chadi
    Galy, Romain
    Benyamina, Amine
    Reynaud, Michel
    Bonhomme-Faivre, Laurence
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 41 (03) : 1011 - 1016
  • [2] TESTING FOR THE EQUALITY OF AREA UNDER THE CURVES WHEN USING DESTRUCTIVE MEASUREMENT TECHNIQUES
    BAILER, AJ
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1988, 16 (03): : 303 - 309
  • [3] CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin
    Bland, TM
    Haining, RL
    Tracy, TS
    Callery, PS
    [J]. BIOCHEMICAL PHARMACOLOGY, 2005, 70 (07) : 1096 - 1103
  • [4] EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL ON ATPASES IN MOUSE-BRAIN SUBCELLULAR-FRACTIONS
    BLOOM, AS
    HAAVIK, CO
    STREHLOW, D
    [J]. LIFE SCIENCES, 1978, 23 (13) : 1399 - 1404
  • [5] MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients
    Bonhomme-Faivre, L
    Devocelle, A
    Saliba, F
    Chatled, S
    Maccario, J
    Farinotti, R
    Picard, V
    [J]. TRANSPLANTATION, 2004, 78 (01) : 21 - 25
  • [6] Sparse sampling for assessment of drug exposure in toxicological studies
    Burtin, P
    Mentre, F
    vanBree, J
    Steimer, JL
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1996, 21 (02) : 105 - 111
  • [7] CAMPA D, 2007, ASS ABCB1 MDR1 OPRM1
  • [8] DALTERIO SL, 1987, EUR J PHARMACOL, V7, P91
  • [9] P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries
    Golden, PL
    Pardridge, WM
    [J]. BRAIN RESEARCH, 1999, 819 (1-2) : 143 - 146
  • [10] Urinary pharmacokinetics of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol after controlled oral Δ9-tetrahydrocannabinol administration
    Gustafson, RA
    Kim, I
    Stout, PR
    Klette, KL
    George, MP
    Moolchan, ET
    Levine, B
    Huestis, MA
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2004, 28 (03) : 160 - 167